Applies to the following strength(s): 30 mg ; 50 mg
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Diabetes Type 2
Initial dose: 30 mg subcutaneously once a week, on the same day each week
May be increased to 50 mg subcutaneously once a week if glycemic response is inadequate.
Comments: The day of weekly administration may be changed if necessary as long as the last dose was administered 4 or more days before.
Use: Adjunct therapy to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Renal Dose Adjustments
No adjustment recommended.
Comments: Caution is recommended when initiating or escalating doses in patients with any level of renal impairment.
Liver Dose Adjustments
Data not available
Consider reducing the dosage of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce risk of hypoglycemia.
The US FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for Albiglutide. It includes communication plan. For additional information: www.fda.gov/REMS
-Carcinogenicity of this drug could not be assessed in rodents, but other glucagon-like peptide-1 (GLP-1) receptor agonists have caused thyroid C-cell tumors in rodents at clinically relevant exposures. Human relevance of GLP-1 receptor agonist induced C-cell tumors in rodents has not been determined. It is unknown whether this drug causes thyroid C-cell tumor, including medullary thyroid carcinoma (MTC) in humans.
-This drug is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Counsel patients regarding the potential risk of MTC with the use of this drug and inform them of the symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with this drug.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Data not available
-Administer any time of the day, without regard to meals.
-Inject subcutaneously in the abdomen, thigh, or upper arm.
-If a dose is missed, albiglutide should be administered as soon as possible within 3 days after the missed dose. Resume dosing on their usual day of administration.
-If it is more than 3 days after the missed dose, the patient should wait until the next regularly scheduled weekly dose.
-This drug should be not administered intravenously or intramuscularly.
-Never share a pen between patients, even if the needle is changed; do not reuse or share needles or syringes between patients as this presents a risk for transmission of blood-borne pathogens
-Store unopened Pens in the refrigerator.
-Once Pen is opened, store it in the refrigerator or at room temperature (not to exceed 86F or 30C for up to 4 weeks).
Reconstitution/preparation techniques: The lyophilized powder contained within the Pen must be reconstituted prior to administration. See Patient Instructions for Use for complete administration instructions with illustrations.
-Routine serum calcitonin or thyroid ultrasound monitoring is of uncertain value for early detection of MTC in patients treated with this drug.
-This drug is not recommended as first-line therapy for patients inadequately controlled on diet and exercise because of the uncertain relevance of the rodent C-cell tumor findings to humans.
-This drug has not been studied in patients with a history of pancreatitis; consider alternative antidiabetic therapy in patients with a history of pancreatitis.
-This drug in not a substitute for insulin and should not be used in treating type 1 diabetes mellitus or the treatment of diabetic ketoacidosis.
-This drug has not been studied in combination with prandial insulin.
-This drug has not been studied in patients with severe gastrointestinal disease and is not recommended in these patients.
-Renal: Renal function in patients with renal impairment reporting adverse gastrointestinal reactions
-Immunologic: Signs and symptoms of hypersensitivity reactions
-Patients should understand the potential risk of medullary thyroid cancer with the use of this drug and should be instructed to report symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness).
-The pen should be used within 8 hours of reconstitution prior to attaching the needle; patients should be advised to never share a pen with another person, even if the needle is changed; patients should understand that sharing needles or syringes with another person carries a risk for transmission of blood-borne pathogens
-If using this drug together with insulin, administer as separate injections. Injections may be administered in the same body region but should not be adjacent to each other.
-Use a different injection site each week.
-Report the occurrence of severe abdominal pain that may radiate to the back with or without vomiting.
More about albiglutide
- Other brands: Tanzeum